Xeris Biopharma (NASDAQ:XERS) Insider Sells $116,835.67 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $7.01, for a total value of $116,835.67. Following the sale, the insider directly owned 1,320,176 shares in the company, valued at approximately $9,254,433.76. The trade was a 1.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Beth Hecht also recently made the following trade(s):

• On Tuesday, November 11th, Beth Hecht sold 16,667 shares of Xeris Biopharma stock. The shares were sold at an average price of $7.40, for a total value of $123,335.80.

Xeris Biopharma Trading Down 7.0%

XERS stock traded down $0.49 during midday trading on Tuesday, hitting $6.47. 3,144,537 shares of the company’s stock were exchanged, compared to its average volume of 2,499,296. The firm has a 50 day moving average price of $8.21 and a 200-day moving average price of $6.69. Xeris Biopharma Holdings, Inc. has a 12-month low of $3.14 and a 12-month high of $10.08. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -64.69 and a beta of 0.58.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million during the quarter, compared to the consensus estimate of $74.19 million. On average, sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on XERS. Zacks Research lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Leerink Partners increased their price target on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 19th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Xeris Biopharma in a research note on Friday, November 7th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.58.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently modified their holdings of the business. Cetera Investment Advisers lifted its holdings in Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after acquiring an additional 1,735 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Xeris Biopharma by 7.6% during the second quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock valued at $150,000 after purchasing an additional 2,264 shares during the last quarter. R Squared Ltd grew its holdings in shares of Xeris Biopharma by 27.7% during the first quarter. R Squared Ltd now owns 15,730 shares of the company’s stock valued at $86,000 after purchasing an additional 3,410 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Xeris Biopharma by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock worth $254,000 after purchasing an additional 3,562 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.